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Abstract
Hemagglutinin (HA) of the influenza virus plays a crucial role in the early stage of the viral life cycle by binding to sialic acid
on the surface of host epithelial cells and mediating fusion between virus envelope and endosome membrane for the
release of viral genomes into the cytoplasm. To initiate virus fusion, endosome pH is lowered by acidification causing an
irreversible conformational change of HA, which in turn results in a fusogenic HA. In this study, we describe characterization
of an HA inhibitor of influenza H1N1 viruses, RO5464466. One-cycle time course study in MDCK cells showed that this
compound acted at an early step of influenza virus replication. Results from HA-mediated hemolysis of chicken red blood
cells and trypsin sensitivity assay of isolated HA clearly showed that RO5464466 targeted HA. In cell-based assays involving
multiple rounds of virus infection and replication, RO5464466 inhibited an established influenza infection. The overall
production of progeny viruses, as a result of the compound’s inhibitory effect on fusion, was dramatically reduced by 8 log
units when compared with a negative control. Furthermore, RO5487624, a close analogue of RO5464466, with
pharmacokinetic properties suitable for in vivo efficacy studies displayed a protective effect on mice that were lethally
challenged with influenza H1N1 virus. These results might benefit further characterization and development of novel anti-
influenza agents by targeting viral hemagglutinin.
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Introduction
Influenza A viruses are enveloped RNA viruses. Their genomes
are composed of eight single-stranded, negative-sensed RNA
segments. These viruses cause respiratory diseases in humans and
animals with a high morbidity and mortality [1]. The influenza
pandemic of 1918, also known as the Spanish flu, is believed to
have killed 20 million humans [2]. The reassortment of avian flu
RNA fragments with circulating human viruses caused the other
two pandemics, the 1957 H2N2 ‘‘Asian influenza’’ and the 1968
H3N2 ‘‘Hong Kong influenza’’ [3], [4]. Human beings are facing
the challenges of influenza from various directions. Seasonal
influenza epidemics affect about 5–15% of the world’s popula-
tion. Its complications result in an annual mortality ranging from
250,000 to 500,000. Infection of avian flu strains, mostly H5N1,
has been reported in many Asian countries. Though no frequent
human-to-human spreading has been documented, avian flu
infection was serious and associated with a high mortality of
,60% of infected persons [5], [6]. In early April 2009 a new
swine-origin influenza virus (S-OIV), A (H1N1), emerged in
Mexico. The virus quickly spread worldwide through human-to-
human transmission. In June 2009, the World Health Organi-
zation raised the influenza pandemic alert to the highest level
(level 6) [7].
Currently, seasonal trivalent influenza vaccines and vaccines
specific for H5N1 and swine flu are either available or in clinical
trials. Prophylaxis is an effective method, at least in some
populations, for preventing influenza virus infection and its
potentially severe complications. However, due to continuous
viral antigenicity shifting and drifting that make prediction of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29120future circulating flu strain antigens difficult, and due to the
challenges of rapid mass vaccine production of vaccines during a
pandemic, other anti-influenza therapeutics including small
molecule drugs are highly desirable [8]. There are currently two
types of anti-influenza medicines on the market, influenza
neuraminidase inhibitors, oseltamivir phosphate (Tamiflu) and
zanamivir (Relenza) and viral M2 ion channel blockers amanta-
dine and rimantadine [1]. During 2009 pandemic H1N1 flu, an
experimental neuraminidase inhibitor, peramivir, had been issued
by FDA for an emergency use for hospitalized patients only in
cases where other treatments are ineffective or unavailable [9].
This authorization expired on June 23, 2010. An apparent
limitation of currently available antivirals is the risk of develop-
ment of drug resistance that has been frequently reported for both
neuraminidase and M2 channel inhibitors. To overcome/
attenuate the appearance of drug-resistant viruses and increase
the effectiveness of current anti-flu drugs, it is urgent to discover
therapeutics with a new mechanism of anti-influenza action that
can be used as therapeutic or prophylactic agents either alone or
combined with current antiviral drugs.
Hemagglutinin (HA) is a glycoprotein located on the envelope
of influenza virus particles [10]. Currently, 16 hemagglutinin
subtypes of influenza A viruses have been reported that fall into
two major phylogenetic groupings: group 1 (H1, H2, H5, H6, H8,
H9, H11, H12, H13, and H16) and group 2 (H3, H4, H7, H10,
H14, and H15). HA0, the precursor of HA, is synthesized as a
single polypeptide and cleaved at a specific site by a cellular
protease to yield two subunits, HA1 and HA2. Individual HA1 and
HA2 are linked by a disulfide bond. Three HA1-HA2 dimers form
a homotrimer that is a functional unit of hemagglutinin [11]–[13].
The life cycle of influenza virus infection begins with the binding
between the receptor binding pocket located in the membrane
distal region of HA and sialic acid on the surface of host epithelial
cells. Depending on the type of infected host species, one of the
two types of sialic acids, N-acetylneuraminic acid a (2,3)-Gal or N-
acetylneuraminic acid a (2,6)-Gal, is preferably recognized by HA
protein. After HA-receptor binding, influenza virus enters into the
cell by endocytosis resulting in the formation of a virus-containing
endosome. To release virus genomes into the cytoplasm, fusion
between viral envelope and endosome membrane occurs in an
acidic environment that triggers an irreversibly conformational
change of HA in which the hydrophobic fusion peptide at the N-
terminus of HA2 is released from a buried position. The exposed
HA2 fusogenic domain interacts with endosomal membrane,
initiates a series of structural rearrangements of HA2, and finally
leads to membrane fusion and release of viral RNA genomes [10],
[14]–[16]. The viral genomes of RNA-protein complexes (RNP)
are further translocated into the nucleus where viral RNA
replication occurs.
Interfering HA-mediated fusion has become a strategy of anti-
influenza drug discovery for many years. To date, there are two
types of fusion inhibitors that block influenza infection by either
nonspecifically increasing endosome pH or directly targeting HA
protein. Examples of the first mechanism include chloroquine [17]
and triperiden [18]. By interfering with H
+ pumping on the
endosome membrane, these molecules elevate the energy barrier
for endosome acidification. When intra-endosomal pH fails to
approach the required critical point HA conformational change
does not happen and virus fusion is abolished. In the second
mechanism of fusion inhibition, a small molecule inhibitor directly
binds to HA and blocks HA conformational change. Examples of
fusion inhibitors in this second category are BMY 27709 [19]–
[21], 180299 (a podocarpic acid derivative, [22]), tert-butyl
hydroquinone (TBHQ) [23,24], N-substituted piperidine [25],
and stachyflin [26]. These inhibitors are predominantly influenza
virus group-specific, meaning they are active against either group
1 or group 2, but not both, influenza viruses. Except for TBHQ,
the binding sites of these inhibitors on HA are unknown, although
drug resistance profiling and photoaffinity labeling studies suggest
that these molecules bind to HA2 protein. So far, no preclinical
study of these fusion inhibitors including in vivo efficacy in an
animal model was reported. One exception of the second class of
influenza fusion inhibitors is arbidol, which exhibits a broad
spectrum of anti-viral activities and has been proposed to target
HA based on mechanism of action and drug resistance studies.
This compound has been used in the clinic to treat influenza
infection in Russia [27,28] .
Recently, the binding pocket of tert-butyl hydroquinone
(TBHQ) on HA2 peptide of both H3 and H14 strains has been
determined in a co-crystallization study [24]. It is a hydrophobic
pocket at the interface between HA2 monomers in a prefusion HA
trimer. By blocking HA fusogenic conformational changes in the
low pH environment of the endosome, TBHQ inhibits fusion of
group 2 influenza viruses.
In this study, characterization of an HA inhibitor of influenza
H1N1 viruses, RO5464466, is described. Based on the results of
time course studies in one replication cycle and mechanism of
action studies, this compound is believed to directly target HA and
block fusion by stabilizing the pre-fusion structure of hemagglu-
tinin. In cell-based assays involving multiple rounds of virus
infection and replication, RO5464466 inhibited an established
influenza infection. Moreover, RO5487624, an analogue of
RO5464466, with pharmacokinetic properties for in vivo efficacy
studies showed a protective effect on mice that were lethally
challenged with influenza H1N1 virus. All of these data make it
attractive to further characterize and develop HA inhibitors,
including compounds shown in this report, for potential clinical
use.
Materials and Methods
Ethics statement
All animal studies were approved by the Institutional Animal
Care and Use Committee (IACUC) of Medicilon/MPI Research
LLC with the approve ID of 18003-11021 or approved by the
Ethics Committee for Animal Experiments of the Institute of
Medicinal Biotechnology, Chinese Academy of Medical Sciences.
Animal study was conducted in accordance with the current
facility’s Standard Operating Procedures (SOPs) and in compli-
ance with the Animal Welfare Act. Researchers of Roche Pharma
Research and Early Development monitored all activities in
animal study including the IACUC approval, performance, and
compliance.
Compound synthesis
RO5464466 {3-[(5-Hydroxy-1,3,3-trimethyl-cyclohexylmethyl)-
amino]-benzenesulfonamide} and its derivative compound
RO5487624 were synthesized at Roche Pharma Research and
Early Development, China (Fig. 1). The carboxylic acid form of
Oseltamivir (Tamiflu) was provided by Roche global inventory as
phosphate salt. Oseltamivir was also provided by Shanghai
Institute of Materia Medica, Chinese Academy of Sciences.
Ribavirin was ordered from TCI (Shanghai) Development Co.,
Ltd, China.
Cells and viruses
Madin-Darby canine kidney (MDCK) cells were purchased
from American type culture collection (ATCC) and were
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fetal bovine serum and antibiotics. Influenza A/Weiss/43 (H1N1),
A/PR/8/34 (H1N1), A/Mal/302/54 (H1N1), A/New Jersey/8/
76 (H1N1), and A/Hongkong/8/68 (H3N2) were purchased from
ATCC. Influenza A/Human/Hubei/3/2005 was provided by the
Institute of Virology of Wuhan, China. Influenza A/FM/1/47
mouse adapted strain was provided by the Institute of Virology,
Chinese Academy of Preventive Medicine. All virus strains used in
this study were propagated in 10-day-old embryonated chicken
eggs at 37uC. Virus was harvested 48 h after inoculation as pooled
allantoic fluid. After a brief centrifugation (3,000 rpm at room
temperature for 20 minutes) and virus titer measurement by a
hemagglutination test, virus was aliquoted and stored at a 280uC
freezer.
Viral cytopathic effect (CPE) assay
To measure anti-influenza activity of compounds, MDCK cells
in Gibco, OptiPRO
TM SFM (Invitrogen, cat no: 12309) were
seeded into 96-well plates at a density of 5,000 cells per well. Next
day, compounds were dissolved and serially half-log diluted in
dimethyl sulfoxide (DMSO) first, then further diluted (100 folds)
with Gibco SFM containing trypsin. Compound preparations and
virus (50 plaque formation units, pfu) were added into corre-
sponding wells to make a multiplicity of infection (m.o.i.) at 0.01
and a final trypsin concentration of 2.5 mg/ml. Final compound
concentrations were ranged from 0.3 mM to 100 mM in general or
properly reduced if a compound’s EC50 was below than 0.3 mMi n
an initial test. The testing plates also contained medium control,
cell control, virus control, and compound toxicity control. After a
3-day treatment, cell viability was measured with MTT ((3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Briefly,
20 ml of MTT (5 mg/ml, diluted in culture medium) was added
into each well and incubated at 37uC for 4 hours. Reduced MTT
(formazan) was extracted with acidic isopropanol. Absorbance at
wavelengths of 570 nm and 630 nm (OD570 and OD630) was read
on a microtiter plate reader. After subtraction of background OD
values, dose response curves of half-log concentration vs.
percentage of protection were generated, from which half maximal
effective concentration (EC50) and half maximal toxic concentra-
tion (CC50) were calculated.
Plaque reduction assay
MDCK cell suspension in UltraMDCK serum free medium
(Lonza, cat. no:12-749Q) was seeded into 6-well plates with a
density of 6610
5 cells per well. When monolayer was confluent,
culture medium was removed. 100 pfu of virus as well as
compound prepared in culture medium containing 2.5 mg/ml
trypsin were added into wells. Plates were incubated in a CO2
incubator for 1 hour with several intermittent rockings. After virus
absorption, inoculums were removed and 3 ml of 0.5% low-
melting point agarose overlay prepared in culture medium
containing 2.5 mg/ml trypsin and compound was added into
wells. After incubating plates at 37uC for 3 days, the cell
monolayer was fixed with 4% paraformaldehyde for 1 hour.
Then, agarose overlay was removed and cell monolayer was
stained with 0.5% (w/v) crystal violet prepared in 5% ethanol.
Plaques were counted by visual examination.
Hemagglutination inhibition assay
Hemagglutination inhibition (HI) assay was employed to
evaluate the effect of a compound on virus adsorption to target
cells. Compound in PBS was mixed with an equal volume of
influenza virus that was serially diluted by two-fold in PBS. After
1 hour incubation at room temperature, 50 ml of compound-virus
preparation was mixed with an equal volume of 1% chicken
erythrocyte suspension in PBS in a V bottom 96-well plate. The
mixture was incubated for 1 hour at room temperature before
observing erythrocyte aggregation on the plate.
Hemolysis inhibition assay
Fresh chicken erythrocytes were washed twice with PBS and re-
suspended to make a 2% (v/v) suspension in PBS that was stored
at 4uC until use. 100 ml of compound diluted in PBS was mixed
with an equal volume of virus in a 96-deepwell plate. Allantoic
fluid harvested from virus-inoculated embryonated chicken eggs
was used as virus preparation in hemolysis assay. After incubating
virus-compound mixture at room temperature for 30 minutes,
200 ml of 2% chicken erythrocytes pre-warmed at 37uC was
added. The mixture was incubated at 37uC for another
30 minutes. To trigger hemolysis, 100 ml of sodium acetate
(0.5 M, pH 5.2) was added and mixed well with erythrocyte
suspension. The mixture was incubated at 37uC for 30 minutes for
HA acidification and hemolysis. To separate non-lysed erythro-
cytes, plates were centrifuged at the end of incubation at
1,200 rpm for 6 minutes. 300 ml of supernatant was transferred
to another flat bottom 96-well plate. OD540 was read on a
microtiter plate reader. Percentage of protection was calculated as
[1- (mean of OD540compound 2 mean of OD540PBS)/(mean of
OD540DMSO 2 mean of OD540PBS)]6100%, where mean of
OD540compound, mean of OD540PBS, and mean of OD540DMSO
are the absorbance of compound-, virus-containing samples; the
absorbance of no virus control samples; the absorbance of DMSO-,
virus-containing samples, respectively. IC50 is defined as the
compound concentration that generates 50% of the maximal
protection. Special attention should be paid when a compound is
colorful or is hemolytic. Suitable controls should be set up to adjust
absorption backgrounds since both of those features of a compound
could result in a false negative outcome in hemolysis inhibition
assay.
HA purification and trypsin protection assay
HA was purified by a modification of the published procedure
[21]. After a brief centrifugation to remove insoluble materials,
virus in 300 ml of allantoic fluid was pelleted by an ultracentri-
fugation of 38,500 rpm at 4uC for 2 hours. The virus was
suspended in PBS and subjected to a second ultracentrifugation of
25,000 rpm at 4uC for 3 hours through a discontinuous sucrose
gradient composed of 60%, 45%, and 30% (w/v) of sucrose. Virus
concentrated between 45% and 60% sucrose gradients was
recovered by puncturing the tube with a needle and drawing the
cloudy virus fraction. After diluting virus-containing sucrose with
PBS, the virus was pelleted and resuspended in 1 ml of buffer
(100 mM Tris HCl, pH7.4; 1 mM EDTA; 1 mM 2-b-mercapto-
Figure 1. Chemical structure of RO5464466 (A) and RO5487624
(B), benzenesulfonamide derivatives. RO5464466 and RO5487624
were shown in [29] as compound 28 and 40, respectively.
doi:10.1371/journal.pone.0029120.g001
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bromelain in the solution above at 37uC for 16 hours to release
HA from virus particles. After a centrifugation of 10,000 rpm at
room temperature for 20 minutes, the supernatant was applied to
a Sephacryl-400 gel filtration column equilibrated with PBS.
Elution was carried out at a flow rate of 0.5 ml/min. Fractions
containing bromelain-cleaved HA (BHA) were concentrated in a
Centriprep-30 concentrator to a volume of 2 ml and then were
diluted 10-fold with PBS. For a further purification, BHA-
containing solution was loaded onto an ion exchange column, Q
Sepharose FF. After washing the column with 20 mM phosphate
buffer (monosodium phosphate - disodium phosphate, pH8.0),
BHA was eluted with 20 mM phosphate buffer; 0.3 M NaCl.
BHA was identified by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), and concentrated by a Centriprep-
30 apparatus.
To measure if a compound stabilizes BHA native structure in an
acidic environment, sensitivity of BHA to trypsin digestion was
determined in which only conformationally-changed BHA resulting
from a low pH treatment is cleavable by trypsin. 4–6 mg of purified
BHA was incubated with compound or various controls at 31uC for
15 minutes. The mixture was adjusted with 0.25 M citrate (pH 4.2)
to a final pH of 5.0, and incubated for another 15 minutes at 31uC.
pH of the reaction was then neutralized with 0.25 M Tris.HCl,
pH 9.0 to the final pH of 7.5. 2 mg of trypsin was added to each
reaction and digestion was carried out for 30 minutes at 37uC.
Trypsin-mediated HA cleavage was checked on a 10% SDS-PAGE
gel that was stained with Coomassie blue G-250.
Pharmacokinetic analysis
RO5487624, an analogue of RO5464466, was used in in vivo
pharmacokinetic study. Male CD-1 mice were administrated
either intravenously (i.v.) via the tail vein with 6% solutol and 94%
saline formulation of RO5487624 at 10 ml/kg body weight to
provide a dose of 2 mg/kg, or orally (p.o.) by gavage with a
0.445% microcrystalline cellulose, 0.055% sodium carboxymethyl
cellulose and 1.6% lactose in distilled water at 10 ml/kg body
weight to provide three doses of 30, 100, 200 mg/kg. Blood
samples were collected via jugular vein puncture or vena cava at
5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after i.v.
dose administration and at 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h,
and 24 h after p.o. dose administration, respectively. Blood
samples were centrifuged at 4uC at 2,700 rpm for 15 minutes to
allow plasma separation. Lung samples in orally dosing groups
were collected at 1 h, 4 h, 8 h, and 24 h post administration.
Samples were analyzed individually for RO5487624 by liquid
chromatography-tandem mass spectrometry with a limit of
quantitation of 1 ng/ml. Mean +/2 standard deviation (n=4)
concentrations of RO5487624 were calculated per administration
route, per dose level, and per sampling time. Plasma concentration
versus time profiles were subjected to a noncompartmental
pharmacokinetic analysis using validated WinNonlin software
(Version 5.2, Pharsight Corporation, CA).
In vivo efficacy study
Influenza A virus strain A/FM/1/47 (H1N1) was grown in
embryonated eggs. LD50 (median lethal dose) was determined in
mice after serial dilution of allantoic fluid. 40 LD50 were used for
viral challenge in all groups by intranasal inoculation of Kunming
female mice, 5–7 weeks old, anesthetized by isoflurane.
RO5487624 (200 mg/kg and 50 mg/kg) were administrated
orally, twice per day for 7 days. Oseltamivir (50 mg/kg) and
ribavirin (50 mg/kg) were used as positive controls and adminis-
trated twice per day by either an oral or i.p route, respectively, for
7 days. The first dosage of all treatments was given either 1 h
before (prophylactic) or 3 h after (post exposure prophylaxis) virus
challenge. Survival of the infected animals (10 in each group) was
monitored for duration of 14 days starting from virus challenge.
Results
Anti-influenza activity of RO5464466
RO5464466 is a representative benzenesulfonamide compound
discovered at Roche Pharma Research and Early Development,
China (Fig. 1).
In vitro anti-influenza activity of RO5464466 was measured and
presented in Table 1. RO5464466 possessed similar activities
against four H1N1 strains (A/Weiss/43, A/PR/8/34, A/Mal/
302/54, and A/New Jersey/8/76). However, it failed to exhibit an
apparent inhibitory effect on the replication of two H3N2 strains
(A/Hongkong/8/68 and A/Human/Hubei/3/2005) at a con-
centration of 100 mM in a CPE assay. RO5487624 was
synthesized when majority of studies of RO5464466 was done.
RO5487624 showed a slightly better in vitro anti-influenza activity
when compared to RO5464466 and better pharmacokinetic
properties for in vivo efficacy study (described later). The detailed
synthesis schemes and the structure-activity relationship (SAR)
studies of benzenesulfonamides can be found in a recent
publication [29].
RO5464466 inhibited an early step of influenza virus
infection
To identify the step(s) of influenza life cycle RO5464466 blocks,
we performed a time course study of inhibitory effects of
RO5464466. Since it takes 8 to 10 hours for influenza A/
Weiss/43 virus to produce its progeny viruses after virus
absorption, six 1 to 2-hour treatment intervals covering the whole
life cycle of this virus strain from absorption to progeny production
were used to disclose the time frame when RO5464466 exerts the
maximal effect (Fig. 2A). The compound was applied during each
of these intervals by adding compound and washing plates with
PBS at specific time points. Following the treatment, fresh
compound-free medium was added. DMSO (0.5% in culture
medium) was used as a negative control and added/washed away
at each time frame. All treated cells were harvested at a time point
of 10 h post infection. Virus yield was determined by measuring
TCID50 of every culture well in this experiment. As shown in
Fig. 2A, apparent RO5464466-induced inhibition of virus
amplification was observed when infected cells were treated in
an interval of 0–2 hour post virus absorption. This time frame
corresponds to early steps of influenza virus replication such as
internalization or fusion. Virus yield measured in the 0–2 hour
treatment group was similar to that of absorption control in which
culture cells were placed into a 280uC freezer immediately after
the virus absorption step to eliminate any possible virus replication
and progeny production. These data suggest that RO5464466
completely blocks virus replication when administrated during the
0–2 hour post absorption interval. Any viruses that were detected
in this group and absorption control group might derive from
residual input viral particles that were not completely washed
away after the absorption step. Treatment during other time
frames did not significantly inhibit virus yield when compared to
DMSO control groups. To confirm this result, we chose two time
points, 0–2 hours and 6–8 hours post absorption intervals for a
dose-response study. As shown in Fig. 2B, RO5464466 inhibited
virus replication with an EC50 of 4 mM when added at 0–2 hours.
This inhibitory effect was not apparent (EC50.31.6 mM) when the
compound was added at 6–8 hours post absorption.
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hemolysis
The early influenza virus replication steps include virus
absorption, internalization of virus to form a virus-containing
endosome, and fusion. Results in the time course study indicated
that RO5464466 did not exert an inhibitory effect on virus
absorption step (21 to 0 hour interval in Fig. 2A). To further
support this claim, hemagglutination-inhibition test was used in
which aggregation of chicken erythrocytes was the consequence of
the binding between viral hemagglutinin and sialic acid receptors
on the surface of the cells. At a concentration of 10 mM,
RO5464466 did not have an inhibitory effect on hemagglutination
Table 1. Comparison of in vitro anti-influenza activities of RO5464466 and RO5487624.
CPE (EC50)
a
CC50
b
Homelysis
assay (IC50)
BHA trypsin
sensitivity
c
A/New Jersey
/8/76 (H1N1)
A/Mal/302
/54 (H1N1)
A/Weiss/
43 (H1N1)
A/PR/8/34
(H1N1)
A/Hongkong
/8/68 (H3N2)
A/Human/Hubei
/3/2005 (H3N2)
RO5464466 0.28 0.66 0.21 0.58 .100 .100 .100 0.29 +
RO5487624 0.09 0.45 0.09 0.21 .100 .100 71 0.25 +
a: All numbers (EC50,C C 50,a n dI C 50) are means of three independent experiments and shown in micromolar concentrations;
Some data from A/Weiss/43 have been shown in [29].
b: MDCK cells were used;
c: + means nearly 100% protection of BHA from trypsin degradation in the presence of compounds (10 mM).
doi:10.1371/journal.pone.0029120.t001
Figure 2. Time course of the inhibitory effect of RO5464466 in one cycle of influenza virus replication. (A) MDCK cells were seeded into
24-well plates at a density of 2610
5 cells per well. 140 pfu of influenza A/Weiss/43 (H1N1) were inoculated into each wells when the cell monolayer
was confluent. After one hour of virus absorption on ice, culture wells were washed with PBS and the plates were incubated with medium containing
2 mg of trypsin per ml in a CO2 incubator at 37uC (0 hour post-infection). RO5464466 was added at 21 to 0 (absorption), 21 to 2, 0 to 2, 2 to 4, 4 to 6,
6 to 8, 8 to 10 hour post-infection at a final concentration of 20 mM. After each treatment period, the monolayer was washed and incubated in fresh
medium until 10 hour post-infection. Every condition was tested in triplicate. Virus yield was determined by measuring TCID50 of the cell lysates.
Open columns, the mean virus yield for cells treated with RO5464466; closed columns, the mean virus yield of DMSO controls; vertical lines, standard
deviation (n=3). One of three independent experiments was shown. *, results significantly different from that of each control by Student’s t test
(P,0.05). (B) Dose-response curves of RO5464466 at 0–2 and 6–8 hours post absorption intervals. Conditions of cell seeding and culturing, virus
harvest, and TCID50 measurement were the same as described in (A). Virus-infected cell layer was treated with RO5464466 at concentrations ranging
from 0.1 to 31.6 mM (six half-log diluted doses) for 2 hours at two intervals before incubated in no-compound fresh medium.
doi:10.1371/journal.pone.0029120.g002
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that RO5464466 doesn’t interfere with virus-receptor interaction.
To study if RO5464466 targets on virus fusion, a hemagglutinin-
mediated hemolysis assay was employed, in which hemagglutinin
of influenza virus binds to sialic acid receptors of chicken
erythrocytes as described in the hemagglutination inhibition test.
To trigger hemolysis, virus-cell suspension was acidified briefly to
initiate HA conformational changes and generate ‘‘holes’’ on the
surface of cells to release hemoglobin content from the cells.
RO5464466, when added into virus-cell suspension before
acidification, inhibited hemolysis in a dose-dependent manner
with an IC50 of 0.29 mM (Table 1). To make sure that the
inhibitory effect of RO5464466 on hemolysis could exist in a
broad range of pH that was used to acidify virus–cell suspension,
pH-dependence of hemolysis in the presence or absence of the
compound was evaluated by adjusting virus-absorbed erythrocytes
to different pH values before measuring the release of hemoglobin.
As a control, erythrocyte suspension alone was also adjusted to the
same pH to measure the extent of hemolysis caused by acidic pH
itself. As shown in Fig. 3, when pH was lower than 5, hemolysis
was triggered by acidic pH (pH control: no virus added to the
suspension of chicken erythrocytes) to an extent where no
difference was detected no matter if RO5464466 was present or
not. On the other end, when pH was 5.5 or higher, no significant
pH-mediated hemolysis was observed no matter if virus or
compound exists, indicating HA conformational changes would
not occur efficiently under these conditions. For the four pH values
tested in the middle between 4.96 and 5.5, hemolysis caused by a
low pH alone was nearly none or at a lower level when compared
to the pH groups in the left end of Fig. 3. Under these pH values
(5.03, 5.05, 5.1, and 5.2), adding influenza virus apparently
increased the extent of hemolysis (shown as higher OD540 values in
DMSO controls where virus and erythrocytes were present but
there was no RO5464466). The overall hemolysis in DMSO
controls might be composed of two different components: HA-
mediated hemolysis under a low pH and hemolysis triggered by a
low pH itself. In the presence of 10 mM RO5464466, HA-
mediated hemolysis was completely blocked at all four pH values
tested since the OD curve of RO5464466 was very close to the
curve of pH control. This result indicates a possibility that
RO5464466 may interfere with the acidification-induced confor-
mational change of HA that is a prerequisite for virus-induced
hemolysis. In addition, RO5464466 didn’t result in a significant
increase of OD540 when compared with the values observed in
both pH and DMSO control groups at pH 5.5 and 6.0 (at the
right end of Fig. 3) where no apparent hemolysis was observed.
This data suggests RO5464466 itself is not hemolytic. As negative
controls, two known influenza virus inhibitors, oseltamivir and
ribavirin, did not show any effect on hemolysis (data not shown).
RO5464466 protected hemagglutinin from trypsin
digestion
To further confirm that the target of RO5464466 is HA, we
studied hemagglutinin sensitivity to trypsin digestion in the
presence or absence of RO5464466. Bromelain-cleaved HA
(BHA) was isolated with a purity of ,95% based on Coomassie
blue staining of an SDS-PAGE gel (see Materials and Methods). It
has been reported that a low pH (such as pH 5.2) environment
triggers a characteristic conformational change of BHA, resulting
in exposure of internal trypsin cleavage sites that renders BHA
sensitive to trypsin digestion. As shown in Fig. 4A, BHA without
acidification was resistant to trypsin digestion. However, after 15-
minute incubation at pH5.2, both HA1 and HA2 in BHA were
sensitive to trypsin. While ribavirin, a negative control, failed to
show a protective effect on BHA, RO5464466 and RO5487624
completely protected HA from trypsin digestion. Fig. 4B shows
that RO5464466 protected BHA in a dose-dependent manner
with a half efficacious concentration of ,1 mM.
To further study RO5464466’s protective effect on BHA, pH of
compound-BHA solution was adjusted from 5.5 to 4.5. After a
brief incubation in acidic solution and a subsequent neutralization
step, BHA was treated with trypsin as above. As shown in Fig. 4C,
RO5464466 effectively protected BHA from trypsin-caused
degradation throughout the tested pH values, except pH 4.5
where a slight trypsin-caused degradation of BHA was observed.
This result reinforces the claim that RO5464466 stabilizes HA
structure in a low pH environment.
To rule out the possibility that the protective effect of
RO5464466 on trypsin-catalyzed degradation of BHA was due
to direct inhibition of trypsin activity, RO5464466 was mixed with
BHA either before or after acidification and neutralization steps,
followed by trypsin digestion. As shown in Fig. 4D, the compound
exerted a protective effect on BHA only when it was added into
the reaction prior to acidification. Taken together, these results
suggest that the compound binds to BHA and prevents its overall
structure from low pH-triggered conformational changes.
RO5464466 inhibited an established infection in vitro
To study anti-influenza virus activity of RO5464466 in more
details, we used the production of progeny influenza virus as an end
point to compare the in vitro activities of RO5464466 and other
reference influenza reagents. After a treatment with RO5464466 at
concentrations ranging from 0.0316 to 3.16 mM or oseltamivir at
concentrations of 0.0316 to 3.16 mM or ribavirin at concentrations
ranging from 0.316 to 31.6 mM for 48 hours, infected cells were
subjected to a freeze-thaw to release viruses into the supernatant. All
treatments including DMSO control were done in duplicate wells.
TCID50 was determined to compare the yield of progeny virus
Figure 3. RO5464466 inhibited HA-mediated hemolysis of
chicken erythrocytes. After mixing RO5464466 with virus-containing
allantoic fluid, suspension of freshly prepared chicken erythrocytes was
added. The mixture was then acidified with different pH from 4.85 to 6.
The suspension was incubated at 37uC for 30 minutes. The final
concentration of RO5464466 was 10 mM. After a brief spin, supernatants
containing released hemoglobin were transferred to a second plate for
measuring OD540. As a control, suspensions of erythrocytes alone were
acidified (pH control) similarly to measure low pH-caused hemolysis. In
the DMSO control group, every step was the same as described in
RO5464466 group except the testing compound was omitted. All
conditions were tested in duplicated wells. *, results significantly
different (RO5464466 treated samples vs. DMSO controls) by Student’s t
test (P,0.05).
doi:10.1371/journal.pone.0029120.g003
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RO5464466 treatment at 3.16 mM caused an 8-log reduction of virus
yield. Ribavirin also strongly inhibited progeny virus production at
concentrations of 10 and 31.6 mM. Oseltamivir at 3.16 mMr e s u l t e di n
a 5-log virus yield reduction. This effect was attenuated at the lower
concentrations. In a second experiment, dynamics of progeny virus
production in the presence of an inhibitor was studied. Infected
MDCK cells were treated with RO5464466 and ribavirin at the
highest concentration that was used in the previous experiment. At
different time points of the treatment, virus was harvested and
measured for the determination of progeny virus titer in each
treatment group. In Fig. 5B, RO5464466 showed a strong inhibition
at all time points of 24, 48, and 72 hours post infection. Progeny virus
titer in the RO5464466 treated group was barely detectable at a
baseline level. However, inhibitory effects of ribavirin became weaker
as the treatment was elongated from 24 to 72 hours. These results
suggest that RO5464466 has a stronger and longer-lasting in vitro anti-
influenza activity than ribavirin.
In the experiments described above, RO5464466 and virus
were added to the cell monolayer simultaneously. To mimic a real
influenza infection situation in which virus infection occurs before
pharmacological intervention, a plaque formation assay was
designed to address if RO5464466 could inhibit overall virus
amplification by blocking virus fusion in an established influenza
infection, where the formation of a plaque is the result of multiple
rounds of virus infection and replication initiated by a single
infectious virus. In the following experiment, the timing of the
addition of RO5464466 was different, ranging from immediate
addition, 12 hours, 24 hours, or 48 hours after virus absorption.
As shown in Fig. 5C, RO5464466 completely protected cell
monolayer against cell death (no visible plaques) when it was
added to cell cultures at both 0 and 12 hours post absorption.
Addition of the compound at 24 hours post absorption still
inhibited virus infection, reflected by the appearance of small
plaques when compared with plaques observed in 48 hour post
absorption or DMSO control groups. This result suggests that
RO5464466, through inhibiting virus fusion, may significantly
attenuate an established infection where multiple rounds of
influenza virus infection and amplification were ongoing.
Pharmacological properties and bioavailability of
RO5487624
RO5487624 is a close analogue of RO5464466 (Fig. 1) and has
in vitro anti-influenza activities similar to RO5464466. Its
mechanism of action as an HA inhibitor was confirmed by trypsin
sensitivity assay (Fig. 4A) and HA-mediated hemolysis assay (data
not shown). We chose it for the following studies because
RO5487624 possessed in vivo pharmacological properties better
than that of RO5464466.
A single dose pharmacokinetics study of RO5487624 was
performed in male CD-1 mice. After i.v. administration of
RO5487624 at 2 mg/kg in Solutol-saline solution, plasma concen-
trations declined with a terminal half life (t1/2) of 2.5 hours, and
total plasma clearance was 53 mL/min/kg, which is moderate. The
mean values of AUC (0-t) and AUC (0-inf) were 587 and 629 ng*h/
ml, respectively. In oral administrations of RO5487624 at 30, 100,
200 mg/kg, Cmax and AUC were increased in a dose-dependent
manner in plasma. Lung-plasma concentration ratios following oral
administration were in a range of 1 to 3 in most time points and
dosage groups. Based on the AUC (0-inf) values of intravenous and
oral dose, the oral bioavailability of the compound in CD-1 mouse
was estimated to be greater than 70%. After an adjustment of in vitro
EC90 (0.3 mM) by compound’s protein binding, plasma concentra-
tion of RO5487624 required to result in EC90 effect in vivo was
calculated to be 3.75 mM. A corresponding line of this in vivo EC90
was shown inFig.6. It was estimated that at a single dose of 100 and
200 mg/kg p.o., plasma concentration of RO5487624 was higher
than its EC90 for a period of 7 and 10 hours, respectively. This
estimation supplies a rationale of execution of an in vivo efficacy
study of RO5487624.
Figure 4. SDS-PAGE of trypsin sensitivity assay showing RO5464466 protected BHA from trypsin digestion in pH-dependent and
dose-dependent manner. (A) 6 mg BHA was incubated with compounds of different concentrations for 15 minute at 31uC prior to acidification to
pH 5.0 with 0.25 M citrate (pH 4.2). The mixture was neutralized to a final pH of 7.5 and treated with 2 mg of trypsin for 30 minutes at 37uC. The
extent of trypsin cleavage on BHA was analyzed on a 10% SDS-PAGE gel. MW was shown on the right in thousands. Untreated BHA, trypsin alone,
BHA trypsin digestion without a prior acidification step were used as controls and included in this figure. (B) Dose-dependent protection of BHA by
RO5464466. (C) pH-dependent protection of BHA by RO5464466. After incubated with 10 mM of RO5464466, BHA was acidified to different final pH
shown on the top of the gel before neutralization and trypsin digestion. As a negative control, DMSO-treated BHA was adjusted to two pH values (5.0
and 5.2) before neutralization and trypsin digestion. (D) RO5464466 protected BHA from trypsin digestion not by directly inhibiting trypsin enzymatic
activity. RO5464466 was added into the reaction either before or after acidification of BHA.
doi:10.1371/journal.pone.0029120.g004
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With respect to in vivo efficacy of RO5487624, mice infected with 40
LD50 of an H1N1 strain were administrated with RO5487624 or
other positive controls, ribavirin and oseltamivir, starting at either 1 h
before or 3 h after virus challenge (see materials and methods). The
efficacy of these compounds was evaluated on the basis of mean
survivaldayandsurvivalratemeasuredfor14days.AsshowninFig.7,
RO5487624 displayed a significant efficacy in all treated groups in
terms of mean survival day (P,0.05). Consistently, a previous in vivo
experiment of RO5487624 with the same administration route and
dosages as described in Fig. 7 showed a similar elongation of mean
survival day (P,0.05), in which only post exposure prophylaxis (3 h
after virus challenge, 17 LD50) of the compound was studied. In Fig. 7,
prophylactic administration of RO5487624 and two positive controls
displayed better efficacies than post exposure prophylaxis administra-
tion. RO5487624 significantly increased survival rate (P,0.05) when
given 1 h prior to virus inoculation. These in vivo data suggest that
RO5487624,asan HAfusion inhibitor,has aprotective effecton mice
that were lethally challenged with influenza H1N1 virus.
Before in vivo efficacy study, we administrated mice with
RO5487624 orally at the dosages of 200 mg/kg and 50 mg/kg,
respectively, twice a day for 7 days without virus challenge.
Survival of the treated animals and body weight were monitored
for 14 days starting from the first day of compound dosing. We did
not find any animal death and statistically significant body weight
changes in this experiment.
Discussion
In this study, we showed that RO5464466 and RO5487624,
two representative compounds of benzenesulfonamide, inhibit
fusion as well as overall replication of H1N1 influenza viruses in
both in vitro and in vivo models in which multiple rounds of virus
infection and amplification occur.
Figure 5. RO5464466 blocked the production of progeny virus and inhibited an established influenza virus infection. (A) Decrease of
progeny virus production in cells treated with RO5464466 and other reference compounds. 12-well plates were seeded with MDCK cells at a density of
1.5610
5 cells per well. On the next day, serially diluted compounds and 150 pfu virus were added per well. 48 hours later, treatment was stopped and
viral titer in cell monolayer was measured in TCID50. Virus yield was shownin a log scale,a mean of twowells. (B)Dynamics of virus yieldreductionin the
presence of inhibitors. In this experiment, all treatments began at the same time when virus was added into culture wells but were stopped at different
time points of 24, 48, and 72 hours post-infection, respectively. (C) Inhibition of plaque formation by RO5464466. Details of seeding MDCK cells into 6-
well plates and infecting monolayers with influenza A/Weiss/43 (H1N1) were described in the plaque reduction assay in the section of Materials and
Methods. Instead of using 3 ml of agarose-containing overlay for each well, 2.5 ml of overlay was used. At each time point (0, 12, 24, 48 hours post-
infection), 2.5 ml of culture medium that contained compound of 2-fold final concentration was added on the top of the overlay. At 72 hours post-
infection, cell monolayers were fixed and stained to show plaques. Representative data of three independent experiments was shown.
doi:10.1371/journal.pone.0029120.g005
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(Fig. 2) suggested that the benzenesulfonamides inhibited an early
step of influenza replication but did not interfere with virus
absorption or receptor binding step. The latter claim was
supported by hemagglutination inhibition assay where the
presence of the compound failed to show any inhibitory effect
on virus-induced hemagglutination of chicken red blood cells. To
further investigate the compound’s mechanism of action, HA-
mediated hemolysis assay of chicken red blood cells and trypsin
sensitivity assay using purified HA were performed. As shown in
Figure 3, RO5464466 completely blocked hemolysis triggered by a
short exposure of virus-absorbed chicken red blood cells in low pH
environments. Since virus absorption and HA conformational
changes are two key events required for hemolysis, the blockage
Figure 6. Pharmacokinetic analysis of RO5487624. Mean plasma concentration-time profiles of RO5487624 after an oral dose (30 mg/kg, e,
100 mg/kg %, and 200 mg/kg, D) to CD-1 mice. Vertical lines are standard deviation of each group (n=3). Concentration corresponding to
RO5487624’s EC90 after protein binding adjustment is marked by a dotted line.
doi:10.1371/journal.pone.0029120.g006
Figure 7. In vivo efficacy of RO5487624. 40 LD50 of A/FM/1/47 (H1N1) were used for viral challenge in all groups by intranasal inoculation. The
first dosage of all treatments was given either 1 h before (A) or 3 h after (B) virus challenge (see details in Materials and Methods section). Mice in
untreated control group were orally administrated with PBS twice a day for 7 days. Animals (n=10 in each group) was monitored for 14 days starting
from virus challenge. Data was analyzed with Chi-square for mortality rate, * P,0.05; ** P,0.001, and with Kaplan-Meier for mean survival day, #
P,0.05; ## P,0.001, respectively.
doi:10.1371/journal.pone.0029120.g007
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conformational changes. This hypothesis was confirmed in an HA
trypsin sensitivity assay where characteristic changes of bromelain
cleaved HA (BHA) were inhibited in the presence of RO5464466,
rendering BHA resistant to trypsin digestion. In the literature,
small molecules can bind to HA and block influenza fusion by two
different mechanisms: stabilizing or destabilizing HA overall
structures [5], [19]–[21], [24], [25], [30]. An HA destabilizer,
represented by C22, inhibits virus fusion by prematurely triggering
HA conformational changes [30]. Nevertheless, this effect cannot
protect HA from trypsin digestion since HA conformational
changes do occur in the presence of a destabilizer. Based on our
data, RO5464466 and RO5487624 are HA stabilizers that abolish
influenza virus fusion by blocking HA conformational changes in
low pH environments.
To explore the therapeutic value of benzenesulfonamides, a
plaque formation assay was employed where multiple rounds of
influenza virus infection, replication, and death of infected cells
were involved. RO5464466 can attenuate an established infection
reflected by the results that no plaque or only small-sized plaques
were observed when the compound was added 12 to 24 hours post
infection. Furthermore, by inhibiting virus fusion, RO5464466
completely blocked the production of progeny influenza virus in
an in vitro cell based system (Fig. 5, B) at a concentration of
3.16 mM, which is about 10 times the EC50 (CPE assay) of the
compound. Consistent with its in vitro anti-influenza activities, a
benzenesulfonamide compound exhibited an in vivo efficacy in
mice that were challenged with an H1N1 virus strain. At this stage,
in vivo efficacy of benzenesulfonamides represented by RO5487624
was weaker than that of ribavirin or oseltamivir. Besides
differences of mechanism of action of these chemicals, limited
exposure in plasma and lungs and high protein binding of
RO5487624 might be reasons attributable to overall in vivo
outcomes. Improvements on pharmacokinetic properties of
benzenesulfonamides are required for its further development.
Recently, several studies have shown that neutralizing antibod-
ies can be elicited against HA2, a more conserved part than HA1 of
hemagglutinin [31]–[33]. These antibodies target the stem region
of HA2 and can protect mice against challenge with influenza A
viruses. Like HA small molecule inhibitors reported previously,
antibody-mediated protection was also group-specific. For exam-
ple, monoclonal antibody 12D1 elicited with an H3-based HA2
immunogen cannot prevent infections of group one influenza
viruses [31]. In this report, benzenesulfonamides show activities to
several influenza H1N1 strains. However, it is possible for this
chemical series to behavior like other group specific HA inhibitors
and block replication of other members of group one influenza
viruses besides H1N1. Taken together, it might be necessary to
combine two or more different types of small molecule inhibitors
or antibodies against HA for a full coverage of the anti-influenza
spectrum for potential clinical use.
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